EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Allosteric modulation of protein kinase A in individuals affected by NLPD ‐ PKA , a neurodegenerative disease in which the PRKAR1B L50R variant is expressed

Tal Benjamin-Zukerman, Valeria Pane, Rania Safadi-Safa, Meir Solomon, Varda Lev-Ram, Mohammad Aboraya, Anwar Dakwar, Daniela Bertinetti iD, Andrew Hoy, Merel O Mol, John van Swieten, Rodrigo Maillard und 2 weitere

The FEBS Journal · 2025-09 · 292 (18) · 4808-4832

DOI: 10.1111/febs.70098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, online erschienen am 17.04.2025. Verfasst von Tal Benjamin-Zukerman und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel. Hauptthemen laut MEDLINE: Cyclic AMP-Dependent Protein Kinases, Neurodegenerative Diseases, Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Cancer Research Fund, United States-Israel Binational Science Foundation, Israel Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protein kinase A (PKA) is a crucial signaling enzyme in neurons, with its dysregulation being implicated in neurodegenerative diseases. Assembly of the PKA holoenzyme, comprising a dimer of heterodimers of regulatory (R) and catalytic (C) subunits, ensures allosteric regulation and functional specificity. Recently, we defined the RIβ‐L50R variant as a causative mutation that triggers protein aggregation in a rare neurodegenerative disease, neuronal loss, and parkinsonism driven by a PKA mutation (NLPD‐PKA). However, the mechanism underlying uncontrolled PKA allosteric regulation and its connection to the functional outcomes leading to clinical symptoms remains elusive. In this study, we established an in vitro model using patient‐derived cells for a personalized approach and employed direct measurements of purified proteins to investigate disease mechanisms in a controlled environment. Structural analysis and circular dichroism spectroscopy revealed that cellular protein aggregation resulted from misfolded RIβ‐subunits, preventing holoenzyme assembly and anchoring through A‐kinase anchoring proteins (AKAPs). While maintaining high affinity to the C‐subunit, the resulting RIβ‐L50R:C heterodimer exhibits reduced cooperativity, requiring lower cAMP concentrations for dissociation. Consequently, there was an increased translocation of the C‐subunit into the nucleus, impacting gene expression. We successfully controlled C‐subunit translocation by introducing a mutation that decreased RIβ:C dissociation in response to elevated cAMP levels. This research thus sets the stage for developing therapeutic strategies that modulate PKA assembly and allostery, thus exerting control over the unique molecular signatures identified in the disease‐associated transcriptome profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclic AMP-Dependent Protein KinasesNeurodegenerative DiseasesCyclic AMP-Dependent Protein Kinase RIIbeta SubunitHumansAllosteric RegulationMutationA Kinase Anchor Proteins

Stichwörter der Autor:innen

PRKAR1Ballosteryholoenzyme assemblyneurodegenerative diseaseprotein kinase A

Substanzen

Cyclic AMP-Dependent Protein KinasesCyclic AMP-Dependent Protein Kinase RIIbeta SubunitA Kinase Anchor Proteins

Autor:innen und Institutionen

  • The Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
  • Department of Biochemistry, University of Kassel, Germany.
  • Department of Pharmacology, University of California, San Diego, La Jolla, CA, USA.
  • Department of Chemistry, Georgetown University, Washington, DC, USA.
  • Department of Neurology and Alzheimer Center Erasmus MC, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • The Leslie & Susan Goldschmied (Gonda) Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat-Gan, Israel.

ORCID-Profile: Daniela Bertinetti, Ronit Ilouz

Förderung

  • Israel Cancer Research Fund
  • United States-Israel Binational Science Foundation
  • Israel Science Foundation

Zitieren

APA

Benjamin-Zukerman, T., Pane, V., Safadi-Safa, R., Solomon, M., Lev-Ram, V., Aboraya, M., Dakwar, A., Bertinetti, D., Hoy, A., Mol, M. O., van Swieten, J., Maillard, R., Herberg, F. W., & Ilouz, R. (2025). Allosteric modulation of protein kinase A in individuals affected by NLPD ‐ PKA , a neurodegenerative disease in which the PRKAR1B L50R variant is expressed. The FEBS Journal, 292(18), 4808-4832. https://doi.org/10.1111/febs.70098

Vancouver

Benjamin-Zukerman T, Pane V, Safadi-Safa R, Solomon M, Lev-Ram V, Aboraya M, et al. Allosteric modulation of protein kinase A in individuals affected by NLPD ‐ PKA , a neurodegenerative disease in which the PRKAR1B L50R variant is expressed. The FEBS Journal. 2025;292(18):4808-4832. doi:10.1111/febs.70098

BibTeX
@article{BenjaminZukerman2025,
  author = {Benjamin-Zukerman, Tal and Pane, Valeria and Safadi-Safa, Rania and Solomon, Meir and Lev-Ram, Varda and Aboraya, Mohammad and Dakwar, Anwar and Bertinetti, Daniela and Hoy, Andrew and Mol, Merel O and van Swieten, John and Maillard, Rodrigo and Herberg, Friedrich W and Ilouz, Ronit},
  title = {Allosteric modulation of protein kinase A in individuals affected by NLPD ‐ PKA , a neurodegenerative disease in which the PRKAR1B L50R variant is expressed},
  journal = {The FEBS Journal},
  year = {2025},
  volume = {292},
  number = {18},
  pages = {4808--4832},
  doi = {10.1111/febs.70098}
}
Kostenlos starten →